© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 13th 2022, 1:00pm
Closing out their discussion on cardiovascular disease in prostate cancer, experts share their hopes for future evolution of the treatment landscape.
April 6th 2022, 1:20pm
Shared insight on the value of multidisciplinary care and its current state in cardiovascular disease and prostate cancer.
April 6th 2022, 1:00pm
Maria Lopes, MD, MS, elucidates the potential for quality measures and coverage policies to incorporate cardiovascular disease (CVD) and improve outcomes in prostate cancer.
March 30th 2022, 1:20pm
Experts share insight on the need for clinical or real-world evidence to further solidify cardiovascular disease risk as an actionable factor in prostate cancer.
March 30th 2022, 1:00pm
Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.
March 23rd 2022, 1:20pm
Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.
March 23rd 2022, 1:00pm
Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.
March 16th 2022, 1:20pm
Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.
March 16th 2022, 1:00pm
A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.
March 9th 2022, 2:20pm
Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.